Recent clinical data published in JAMA Network Open reveals that routine daily supplementation with a specific multistrain probiotic formula significantly lowers the risk of death and necrotizing enterocolitis (NEC) in very preterm infants. Evaluated across neonatal intensive care units in Sweden and the Netherlands, this intervention highlights a highly favorable benefit-risk profile for neonatal care.
Necrotizing enterocolitis remains one of the most devastating gastrointestinal complications faced by very preterm infants, driving high rates of neonatal morbidity and mortality. Characterized by severe intestinal inflammation and tissue destruction, NEC typically develops when an infant’s gut experiences dysbiosis—a dangerous microbial imbalance marked by a loss of protective commensal bacteria and a subsequent overgrowth of pathogenic microbes. Clinical researchers have increasingly turned toward targeted microbiome restoration as a viable preventative strategy, examining whether specific bacterial strains can safely reinforce the intestinal mucosal barrier and suppress harmful pathogens.
Evaluating Population-Wide Probiotic Implementation in Swedish NICUs
A comprehensive study led by researchers from Sweden’s Karolinska Institutet analyzed data from the Swedish National Quality Registry, reviewing premature infants admitted across 38 neonatal intensive care units (NICUs) from 2017 through 2024. The investigation specifically targeted infants born between 28 and 31 weeks of gestational age, classified as very preterm. Following a 2020 national recommendation by the Swedish Neonatal Society to introduce prophylactic probiotics, utilization across the country’s NICUs surged from 0 percent to 65 percent by 2024.
Among the 4,695 infants included in the cohort analysis, 1,571 received the probiotic protocol while 3,124 served as the control group without supplementation. Comparing periods before and after the national policy change demonstrated a sharp drop in the composite outcome of death and/or NEC, falling from 3.4 percent down to 1.5 percent. Statistical evaluation via adjusted relative risk (ARR) revealed that probiotic supplementation was associated with a 72 percent lower risk of the combined outcome (ARR, 0.28). When analyzed independently, the risk of death dropped significantly (rate, 0.3 percent vs 1.4 percent; ARR, 0.16), as did the incidence of NEC itself (rate, 0.6 percent vs 2.5 percent; ARR, 0.25).
In Plain English: The Clinical Takeaway
- What was studied: Large-scale hospital data tracking very preterm infants given a daily multistrain probiotic supplement containing Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12, and Streptococcus thermophilus TH-4.
- The core finding: Routine administration of these specific bacterial strains was strongly associated with a dramatic reduction in both necrotizing enterocolitis rates and overall mortality among premature infants.
- Safety profile: Researchers actively monitored for probiotic-associated sepsis and found no increase in infection risks, confirming a reassuring safety margin within population-based settings.
Contrasting European Implementation with North American Protocols
The encouraging findings out of Sweden closely mirror data published late last month in the same journal by researchers in the Netherlands. That multicenter retrospective cohort study examined 1,413 infants across two Dutch NICUs and found that routine implementation of the exact same multistrain probiotic formula cut the incidence of NEC in half—dropping from 11.9 percent down to 5.3 percent (adjusted risk ratio, 0.49). While all-cause mortality in the Dutch cohort remained statistically stable between groups, the targeted reduction in severe bowel pathology reinforced the biological efficacy of the intervention.
International uptake of neonatal probiotics varies widely. Registry data from 2022 indicates that probiotic utilization reached 67 percent in Canada for infants born before 34 weeks, and 54 percent in England and Wales. However, clinical adoption in the United States remains vastly different. A prior assessment of 807 U.S. NICUs revealed that only 17 percent had adopted routine probiotic use by 2019. In 2021, the American Academy of Pediatrics cautioned against the routine use of probiotics in infants weighing less than 2.2 pounds, citing mixed data on efficacy, potential product contamination risks, and the regulatory reality that probiotics are classified as dietary supplements rather than FDA-approved drugs.
| Study Cohort & Region | Sample Size (N) | Probiotic Formulation | Primary Clinical Outcome Impact |
|---|---|---|---|
| Karolinska Institutet (Sweden) | 4,695 infants | Multistrain (B. infantis, B. lactis, S. thermophilus) | 72% lower risk of combined death and/or NEC (ARR, 0.28) |
| Multicenter Study (Netherlands) | 1,413 infants | Multistrain (B. infantis, B. lactis, S. thermophilus) | NEC incidence cut in half from 11.9% to 5.3% (ARR, 0.49) |
As neonatal care networks continue to evaluate accumulating data from European population registries, the balance of evidence increasingly supports the targeted, high-purity deployment of specific probiotic strains to protect vulnerable neonatal gastrointestinal tracts. Ongoing vigilance, strict quality control manufacturing standards, and careful patient monitoring will remain essential as the medical community works to harmonize international clinical guidelines.
References
- JAMA Network Open: Probiotic Implementation and Necrotizing Enterocolitis Risk in Preterm Infants.
- European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN): Guidelines on Probiotics for Preterm Infants.
- Swedish National Quality Registry: Neonatal Care Quality and Outcome Reports.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare provider regarding clinical management decisions for neonatal health conditions.
